Mechanisms of HSK amelioration
Mechanisms of HSK amelioration
批准号:
8597431
负责人:
Patrick M Stuart
金额:
$33.08万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-01-01 至 2015-12-31
关键词:
AddressAntigensBiologyBlindnessCCL2 geneCCL3 geneCCL4 geneCD28 geneCD4 Positive T LymphocytesCD80 geneCXCR3 geneCell surfaceCellsCellular InfiltrationCicatrixClinicalClinical PathologyComparative StudyCorneaCorneal DiseasesCountryDataDefective VirusesDendritesDiseaseEpithelialExperimental ModelsEyeGenerationsGenesGlycoproteinsHerpesviridaeHerpesvirus 1Herpetic KeratitisHumanIL8 geneImmuneImmune responseImmunotherapyIncidenceInfectionInflammationInflammatoryInflammatory InfiltrateInterleukin-6KeratitisKeratoplastyLaboratoriesLeadMacrophage Inflammatory Protein-1MaintenanceMediatingModelingMolecular ProfilingMusNIH MousePathogenesisPathologyPhenotypePlayProteinsRecording of previous eventsRecurrenceRecurrent diseaseRelative (related person)ReportingResistanceRoleSimplexvirusT-LymphocyteTNFRSF5 geneTNFSF5 geneTestingTherapeutic InterventionTimeUnited StatesVaccinatedVaccinationVaccine TherapyVaccinesViralViral AntigensVirusVirus DiseasesVirus LatencyWomanWorkbasechemokinecytokinedesigngenital herpeshuman diseaseimprovedmacrophageneovascularizationpreventprophylacticreactivation from latencyresponsesuccessvaccine evaluationvirus host interaction
中文摘要
单纯疱疹性角膜基质炎(HSK)是一种主要的传染性失明的原因,
美国的视力丧失最常见的原因是复发性间质
疾病,而不是原发性HSK,似乎是免疫的结果-
介导的角膜破坏。大多数实验模型都集中在
而不是复发性角膜炎。我们研究了一个复发性HSK模型,
与人类复发性HSK的许多临床和免疫学特征相似。
虽然目前的数据表明,原发性和复发性HSK是相似的,
在临床病理学、病毒抗原分布、细胞免疫学和免疫学方面存在显著差异。
角膜内浸润,一些细胞因子和趋化因子的重要性
和对疫苗治疗的反应,从而表明,
这两种疾病并不相同。在过去的15年里,我们和其他一些人
实验室已经确定了许多关于复发性HSK的特征。
根据我们最近的数据,共刺激分子
我们已经证明了CD 28在HSK中的核心作用,
但与此同时,它也参与了抑制
从潜伏期自发病毒再激活。我们还表明,CD 137 L是
可能与疾病改善有关。这些数据进一步支持了以下观点:
HSK由Th 1表型的CD 4+细胞介导,更重要的是,
Th 2 T细胞与较少的疾病密切相关。为了测试这些
假设我们将:(1)确定促炎分子的作用,
IL-6、KC(IL-8)、IP 10(CXCL 10)和CCL 4在复发性HSK疾病中的作用
发病机制(2)确定共刺激相互作用在这两个过程中的作用。
复发性HSK和维持病毒潜伏期。(3)我们还将确定
无论是针对或促进这些相互作用的治疗干预,
将通过接种疫苗来改善疾病。导出的信息
从这些研究将导致更好地了解生物学的复发性
HSK在小鼠和人类疾病的延伸。此外,这些研究可以
可能提示更有效的免疫疗法,旨在改善人类
HSK病
英文摘要
Herpetic stromal keratitis (HSK) is a leading cause of infectious blindness in the
United States. Visual loss most commonly results from recurrent stromal
disease, as opposed to primary HSK and appears to be the result of immune-
mediated corneal destruction. Most experimental models have focused on
primary rather than recurrent keratitis. We study a model of recurrent HSK that
mimics many clinical and immunological features of recurrent HSK in humans.
While current data indicates that primary and recurrent HSK are similar, there are
significant differences in the clinical pathology, viral antigen distribution, cellular
infiltration within the cornea, importance of both some cytokines and chemokines
and responses to vaccine therapy, thus suggesting that the immune responses in
these two diseases is not identical. Over the past 15+ years our and a few other
labs have characterized much of what is known concerning recurrent HSK.
Based on our most recent data concerning the role that costimulatory molecules
play in HSK as we have demonstrated the central role that CD28 plays in
mediating this disease, but at the same time is involved in suppressing
spontaneous viral reactivation from latency. We have also shown that CD137L is
likely involved in disease amelioration. These data further support the notion that
HSK is mediated by CD4+ cells of the Th1 phenotype and that more importantly,
Th2 T cells are strongly associated with less disease. In order to test these
hypotheses we will: (1) Determine the role that the proinflammatory molecules
IL-6, KC (IL-8), IP10 (CXCL10), and CCL4 play in recurrent HSK disease
pathogenesis. (2) Determine the role that co-stimulatory interactions play in both
recurrent HSK and in maintenance of viral latency. (3) We will also determine
whether therapeutic intervention, either targeting or promoting these interactions,
will ameliorate disease using a vaccination paradigm. The information derived
from these studies will lead to a better understanding of the biology of recurrent
HSK in mice and by extension human disease. Furthermore, these studies could
possibly suggest more effective immunotherapies designed to ameliorate human
HSK disease.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
CD137 costimulation is associated with reduced herpetic stromal keratitis and with developing normal CD8+ T cells in trigeminal ganglia.
CD137 共刺激与疱疹性基质角膜炎的减少以及三叉神经节中正常 CD8 T 细胞的发育有关。
DOI:
10.1099/jgv.0.001756
发表时间:
2022
期刊:
The Journal of general virology
影响因子:
--
作者:
[Yin,Xiao-Tang, Baugnon,NicholasK, Krishnan,Rohini, Potter,ChloeA, Yarlagadda,Sudha, Keadle,TammieL, Stuart,PatrickM]
通讯作者:
Stuart,PatrickM
CD28 Costimulation Is Required for Development of Herpetic Stromal Keratitis but Does Not Prevent Establishment of Latency.
CD28 共刺激对于疱疹性基质性角膜炎的发展是必需的,但不能阻止潜伏期的建立。
DOI:
10.1128/jvi.00659-19
发表时间:
2019
期刊:
Journal of virology
影响因子:
5.4
作者:
[Yin,Xiao-Tang, Baugnon,NicholasK, Potter,ChloeA, Tai,Shannon, Keadle,TammieL, Stuart,PatrickM]
通讯作者:
Stuart,PatrickM
Herpes simplex keratitis: challenges in diagnosis and clinical management.
单纯疱疹性角膜炎:诊断和临床管理方面的挑战。
DOI:
10.2147/opth.s80475
发表时间:
2017
期刊:
Clinical ophthalmology (Auckland, N.Z.)
影响因子:
--
作者:
[Azher TN, Yin XT, Tajfirouz D, Huang AJ, Stuart PM]
通讯作者:
Stuart PM
DOI:
10.3389/fmicb.2021.798927
发表时间:
2021
期刊:
Frontiers in microbiology
影响因子:
5.2
作者:
[Krishnan R, Stuart PM]
通讯作者:
Stuart PM
Mechanisms of HSK amelioration
-
批准号:8389553
-
项目类别:
-
资助金额:$35.63万
-
财政年份:2011
-
负责人:Patrick M Stuart
-
依托单位:
Mechanisms of HSK amelioration
-
批准号:8026561
-
项目类别:
-
资助金额:$36.25万
-
财政年份:2011
-
负责人:Patrick M Stuart
-
依托单位:
Mechanisms of HSK amelioration
-
批准号:8207849
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2011
-
负责人:Patrick M Stuart
-
依托单位:
THE ROLE OF APOPTOTIC MOLECULES IN HERPETIC STROMAL
-
批准号:7526460
-
项目类别:
-
资助金额:$35.3万
-
财政年份:2009
-
负责人:Patrick M Stuart
-
依托单位:
THE ROLE OF APOPTOTIC MOLECULES IN HERPETIC STROMAL
-
批准号:7935224
-
项目类别:
-
资助金额:$34.44万
-
财政年份:2009
-
负责人:Patrick M Stuart
-
依托单位:
FAS L INDUCED APOPTOSIS IN CORNEA TRANSPLANTATION
-
批准号:6384835
-
项目类别:
-
资助金额:$32.37万
-
财政年份:1999
-
负责人:Patrick M Stuart
-
依托单位:
FAS L INDUCED APOPTOSIS IN CORNEA TRANSPLANTATION
-
批准号:2899161
-
项目类别:
-
资助金额:$27.25万
-
财政年份:1999
-
负责人:Patrick M Stuart
-
依托单位:
FAS L INDUCED APOPTOSIS IN CORNEA TRANSPLANTATION
-
批准号:6179299
-
项目类别:
-
资助金额:$26.94万
-
财政年份:1999
-
负责人:Patrick M Stuart
-
依托单位:
FAS L INDUCED APOPTOSIS IN CORNEA TRANSPLANTATION
-
批准号:6951737
-
项目类别:
-
资助金额:$5.36万
-
财政年份:1999
-
负责人:Patrick M Stuart
-
依托单位:
FAS L INDUCED APOPTOSIS IN CORNEA TRANSPLANTATION
-
批准号:6414277
-
项目类别:
-
资助金额:$6.49万
-
财政年份:1999
-
负责人:Patrick M Stuart
-
依托单位:
FAS L INDUCED APOPTOSIS IN CORNEA TRANSPLANTATION
-
批准号:6524983
-
项目类别:
-
资助金额:$33.2万
-
财政年份:1999
-
负责人:Patrick M Stuart
-
依托单位:
FAS L INDUCED APOPTOSIS IN CORNEA TRANSPLANTATION
-
批准号:6637194
-
项目类别:
-
资助金额:$29.44万
-
财政年份:1999
-
负责人:Patrick M Stuart
-
依托单位:
AMELIORATION OF RECURRENT HERPES KERATITIS
-
批准号:6384708
-
项目类别:
-
资助金额:$22.92万
-
财政年份:1998
-
负责人:Patrick M Stuart
-
依托单位:
Amelioration of recurrent herpes keratitis
-
批准号:6617615
-
项目类别:
-
资助金额:$37.08万
-
财政年份:1998
-
负责人:Patrick M Stuart
-
依托单位:
Amelioration of recurrent herpes keratitis
-
批准号:6751542
-
项目类别:
-
资助金额:$36.12万
-
财政年份:1998
-
负责人:Patrick M Stuart
-
依托单位:
Amelioration of recurrent herpes keratitis
-
批准号:6895084
-
项目类别:
-
资助金额:$37.31万
-
财政年份:1998
-
负责人:Patrick M Stuart
-
依托单位:
Amelioration of recurrent herpes keratitis
-
批准号:7233139
-
项目类别:
-
资助金额:$38.64万
-
财政年份:1998
-
负责人:Patrick M Stuart
-
依托单位:
Amelioration of recurrent herpes keratitis
-
批准号:7059913
-
项目类别:
-
资助金额:$37.63万
-
财政年份:1998
-
负责人:Patrick M Stuart
-
依托单位:
AMELIORATION OF RECURRENT HERPES KERATITIS
-
批准号:6179213
-
项目类别:
-
资助金额:$22.41万
-
财政年份:1998
-
负责人:Patrick M Stuart
-
依托单位:
IA INDUCTION/EXPRES'N IN NON-BONE MARROW-DERIVED CELLS
-
批准号:3029218
-
项目类别:
-
资助金额:$2.93万
-
财政年份:1989
-
负责人:Patrick M Stuart
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: